PRIMARY IMMUNE THROMBOCYTOPENIA
Clinical trials for PRIMARY IMMUNE THROMBOCYTOPENIA explained in plain language.
Never miss a new study
Get alerted when new PRIMARY IMMUNE THROMBOCYTOPENIA trials appear
Sign up with your email to follow new studies for PRIMARY IMMUNE THROMBOCYTOPENIA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug combo aims to tame stubborn blood disorder
Disease control OngoingThis study is testing whether adding a new drug called ianalumab to a standard treatment (eltrombopag) can help adults with a persistent autoimmune bleeding disorder (ITP) maintain safe platelet levels for a longer time. It is for people whose ITP did not respond well enough to o…
Matched conditions: PRIMARY IMMUNE THROMBOCYTOPENIA
Phase: PHASE3 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Mar 31, 2026 12:12 UTC
-
Trial for new bleeding disorder pill withdrawn before starting
Disease control TerminatedThis was an early-stage study to test the safety and find the right dose of a new oral drug called HMPL-523 for adults with immune thrombocytopenia (ITP), a condition where the immune system attacks platelets, causing a risk of bleeding. The study was designed to enroll adults wh…
Matched conditions: PRIMARY IMMUNE THROMBOCYTOPENIA
Phase: PHASE1 • Sponsor: Hutchmed • Aim: Disease control
Last updated Mar 30, 2026 14:34 UTC
-
New long-term injection aims to control dangerous low platelet disorder
Disease control OngoingThis trial is testing the long-term safety and effectiveness of a medication called efgartigimod, given as an injection under the skin, for adults with primary immune thrombocytopenia (ITP). The study aims to see if the treatment can help keep platelet counts at a safer level ove…
Matched conditions: PRIMARY IMMUNE THROMBOCYTOPENIA
Phase: PHASE3 • Sponsor: argenx • Aim: Disease control
Last updated Mar 13, 2026 15:05 UTC